OptraSCAN Announces CytoSiA – A Complete Digital Solution For Scanning And Analysis Of Cytology Slides At Affordable Pricing
“OptraSCAN is redefining cervical cancer screening by introducing CytoSiA, it offers a plethora of features, to effectively screen liquid-based cytology slides, and pap smears to differentiate between normal and abnormal cervical cells using Bethesda classifications on normal to squamous cell carcinoma (NILM/LSIL/HSIL/SCC)”, said Abhi Gholap, Founder of OptraSCAN. With a range of scanning devices handling as low as 50 slides a week to 5000 slides a week at an extremely affordable price,” he further added.
OptraSCANS’s digital scanners can scan cytology slides of size 15x15 mm area at 40x magnification in less than 60 seconds while generating the highest quality image. CytoSia incorporates patented technology- composite imaging which finds all pixels in focus from various Z plane images and stitches back to create a single layer composite image. This composite imaging technology is considerably efficient as compared to traditional Z-Stacking Technology. It allows for rapid and precise screening of the entire slide within seconds. This level of precision and quality is imperative for analyzing the samples. Furthermore, it presents to the screener images of fields that would be essential in providing a cytological interpretation, place them into categories, and filter out the redundancies.
CytoSiA when used as a companion diagnostic tool it notifies pathologists when inconsistencies between their interpretation and the AI algorithm's findings are observed, offering a safeguard against error or misinterpretation, while also improving overall care quality.
For more information visit: https://www.optrascan.com/solutions/cytosia
Features of CytoSiA:
• Automated computation of sample adequacy for the whole slide cytology image
• Identification of abnormal cells and other entities based on morphological features and AI-based classification using Bethesda scoring
• Identification of reactive, endometrial, actinomyces, candida, clue cells, trichomonas vaginalis, and herpes entities
• Identification of entities including blood, inflammation, and lubricant.
“AI-based image analysis requires images that are of superior quality,” said Dr. Aparna Joshi, Medical Director, at OptraSCAN. “Our team has developed an intelligent imaging technology that transforms physical glass cytology slides into digital images with exceptional clarity. Advanced image analysis and standardization are now achievable with this quality of digitization”, she further added.
1798 Technology Drive, Suite 244, San Jose, CA 95110
OptraSCAN® are pioneers in the On-Demand Digital Pathology® System, focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services. An ISO 13485 certified company and CE-marked whole slide scanners for IVD use, OptraSCAN are working to eliminate the barriers to “Go Digital” no matter the size of the pathology lab, the lab’s throughput, or global location.
OptraSCAN’s end-to-end digital pathology solution provides effective acquisition of whole slide images, viewing, storing, real-time sharing, reporting, and AI & ML based Image analysis solutions via On-Demand or outright purchase model. Follow Us on LinkedIn and Twitter.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release OptraSCAN Announces CytoSiA – A Complete Digital Solution For Scanning And Analysis Of Cytology Slides At Affordable Pricing here
News-ID: 2377850 • Views: 327
More Releases from OptraSCAN Inc
Karkinos Healthcare Engages OptraSCAN® Digital Pathology In its Mission of Pers …
OptraSCAN®, a leading end-to-end digital pathology solution provider, today announced that Karkinos Healthcare has begun using the high-performance OptraSCAN Digital pathology platform to enhance care for their patient population. The capabilities of this digital pathology platform improve accessibility to healthcare and the distributed care model. The demand for digital pathology has increased as healthcare institutions have struggled to overcome the challenges of the traditional care model of pathologists working in labs
OptraSCAN® receives CE-IVDR for OS-Ultra™ high-performance Digital Pathology …
SAN JOSE, Calif., July 28, 2022 / -- OptraSCAN® a leading end-to-end digital pathology solution provider, announced that it has received CE-IVDR marking for the OS-Ultra™ scanners, its high-performance product line of brightfield scanners at an extremely affordable price point, including pay-per-scan based OPEX models. OS Ultra™ scanners have a loading capacity of 80 to 480 slides. With no-touch continuous loading, it scans tissues or cells with a 15 mm x
OptraSCAN's Artificial Intelligence-Equipped Digital Pathology Scanner OS-SiA Gr …
SAN JOSE, Calif., May 24, 2022 -- OptraSCAN®, the leading end-to-end digital pathology solution provider, announced its digital pathology scanner OS-SiA has been granted US patent - No 2020/0334814 A1 by the United States Patent and Trademark Office. OS-SiA has inbuilt intelligence to scan, index and analyze pathological samples simultaneously. This will benefit the end-user to view the whole slide scanned image along with analyzed output as an overlay during
OptraSCAN and Inspirata Announce Their Technical Partnership to Strengthen Digit …
SAN JOSE, Calif., Nov. 9, 2021 /PRNewswire/ --OptraSCAN®, a leading end-to-end digital pathology solution provider announces its partnership with Inspirata Inc., a leading provider of digital pathology and cancer informatics solutions. This partnership will allow pathology labs, healthcare networks, and hospitals to acquire digital pathology images without any upfront cost and display them within a world-class workflow solution. "We are excited to be working with Inspirata to support their mission